nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabumetone—PTGS2—colon cancer	0.713	1	CbGaD
Nabumetone—MPO—superior mesenteric artery—colon cancer	0.07	0.535	CbGeAlD
Nabumetone—MPO—endothelium—colon cancer	0.00632	0.0483	CbGeAlD
Nabumetone—MPO—blood vessel—colon cancer	0.00583	0.0446	CbGeAlD
Nabumetone—PTGS1—endothelium—colon cancer	0.003	0.0229	CbGeAlD
Nabumetone—PTGS2—endothelium—colon cancer	0.00287	0.0219	CbGeAlD
Nabumetone—MPO—epithelium—colon cancer	0.00284	0.0217	CbGeAlD
Nabumetone—PTGS1—blood vessel—colon cancer	0.00277	0.0211	CbGeAlD
Nabumetone—PTGS2—blood vessel—colon cancer	0.00264	0.0202	CbGeAlD
Nabumetone—MPO—renal system—colon cancer	0.00263	0.0201	CbGeAlD
Nabumetone—PTGS2—gall bladder—colon cancer	0.00249	0.019	CbGeAlD
Nabumetone—MPO—lymphoid tissue—colon cancer	0.00219	0.0167	CbGeAlD
Nabumetone—MPO—digestive system—colon cancer	0.00216	0.0165	CbGeAlD
Nabumetone—MPO—bone marrow—colon cancer	0.00199	0.0152	CbGeAlD
Nabumetone—MPO—liver—colon cancer	0.00161	0.0123	CbGeAlD
Nabumetone—PTGS2—embryo—colon cancer	0.00158	0.0121	CbGeAlD
Nabumetone—CYP1A2—renal system—colon cancer	0.00144	0.011	CbGeAlD
Nabumetone—PTGS1—epithelium—colon cancer	0.00135	0.0103	CbGeAlD
Nabumetone—PTGS1—smooth muscle tissue—colon cancer	0.0013	0.00992	CbGeAlD
Nabumetone—PTGS2—epithelium—colon cancer	0.00129	0.00984	CbGeAlD
Nabumetone—PTGS1—renal system—colon cancer	0.00125	0.00955	CbGeAlD
Nabumetone—PTGS2—smooth muscle tissue—colon cancer	0.00124	0.00948	CbGeAlD
Nabumetone—MPO—lymph node—colon cancer	0.00123	0.00943	CbGeAlD
Nabumetone—PTGS2—renal system—colon cancer	0.00119	0.00913	CbGeAlD
Nabumetone—CYP1A2—digestive system—colon cancer	0.00118	0.00904	CbGeAlD
Nabumetone—PTGS1—digestive system—colon cancer	0.00102	0.00783	CbGeAlD
Nabumetone—PTGS2—lymphoid tissue—colon cancer	0.000991	0.00758	CbGeAlD
Nabumetone—PTGS2—digestive system—colon cancer	0.000979	0.00748	CbGeAlD
Nabumetone—PTGS1—vagina—colon cancer	0.000905	0.00691	CbGeAlD
Nabumetone—PTGS2—bone marrow—colon cancer	0.000903	0.0069	CbGeAlD
Nabumetone—CYP1A2—liver—colon cancer	0.000881	0.00673	CbGeAlD
Nabumetone—PTGS2—vagina—colon cancer	0.000865	0.00661	CbGeAlD
Nabumetone—PTGS2—liver—colon cancer	0.00073	0.00558	CbGeAlD
Nabumetone—Hepatic failure—Capecitabine—colon cancer	0.000699	0.00446	CcSEcCtD
Nabumetone—Pneumonia—Fluorouracil—colon cancer	0.000697	0.00445	CcSEcCtD
Nabumetone—Hyperuricaemia—Methotrexate—colon cancer	0.000695	0.00443	CcSEcCtD
Nabumetone—Acute coronary syndrome—Fluorouracil—colon cancer	0.000683	0.00436	CcSEcCtD
Nabumetone—Myocardial infarction—Fluorouracil—colon cancer	0.000679	0.00434	CcSEcCtD
Nabumetone—Stomatitis—Fluorouracil—colon cancer	0.000675	0.00431	CcSEcCtD
Nabumetone—Increased appetite—Capecitabine—colon cancer	0.000669	0.00427	CcSEcCtD
Nabumetone—Vasculitis—Methotrexate—colon cancer	0.00066	0.00421	CcSEcCtD
Nabumetone—Dermatitis bullous—Capecitabine—colon cancer	0.000657	0.0042	CcSEcCtD
Nabumetone—Blood uric acid increased—Methotrexate—colon cancer	0.000656	0.00419	CcSEcCtD
Nabumetone—Haemoglobin—Irinotecan—colon cancer	0.000653	0.00417	CcSEcCtD
Nabumetone—Haemorrhage—Irinotecan—colon cancer	0.000649	0.00415	CcSEcCtD
Nabumetone—Agranulocytosis—Fluorouracil—colon cancer	0.000647	0.00413	CcSEcCtD
Nabumetone—Melaena—Methotrexate—colon cancer	0.000629	0.00402	CcSEcCtD
Nabumetone—Gastrointestinal haemorrhage—Capecitabine—colon cancer	0.000628	0.00401	CcSEcCtD
Nabumetone—Visual impairment—Irinotecan—colon cancer	0.000626	0.004	CcSEcCtD
Nabumetone—Haemoglobin—Fluorouracil—colon cancer	0.000625	0.00399	CcSEcCtD
Nabumetone—Haemorrhage—Fluorouracil—colon cancer	0.000622	0.00397	CcSEcCtD
Nabumetone—Aplastic anaemia—Methotrexate—colon cancer	0.000605	0.00386	CcSEcCtD
Nabumetone—Alopecia—Vincristine—colon cancer	0.000589	0.00376	CcSEcCtD
Nabumetone—PTGS1—lymph node—colon cancer	0.000585	0.00447	CbGeAlD
Nabumetone—Chills—Irinotecan—colon cancer	0.000583	0.00372	CcSEcCtD
Nabumetone—Arrhythmia—Irinotecan—colon cancer	0.00058	0.0037	CcSEcCtD
Nabumetone—Liver function test abnormal—Capecitabine—colon cancer	0.00058	0.0037	CcSEcCtD
Nabumetone—Alopecia—Irinotecan—colon cancer	0.000574	0.00366	CcSEcCtD
Nabumetone—Hypokalaemia—Capecitabine—colon cancer	0.000572	0.00365	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.000566	0.00361	CcSEcCtD
Nabumetone—PTGS2—lymph node—colon cancer	0.000559	0.00428	CbGeAlD
Nabumetone—Flatulence—Irinotecan—colon cancer	0.000557	0.00356	CcSEcCtD
Nabumetone—Gastritis—Capecitabine—colon cancer	0.000556	0.00355	CcSEcCtD
Nabumetone—Arrhythmia—Fluorouracil—colon cancer	0.000556	0.00355	CcSEcCtD
Nabumetone—Alopecia—Fluorouracil—colon cancer	0.00055	0.00351	CcSEcCtD
Nabumetone—Asthma—Capecitabine—colon cancer	0.000543	0.00347	CcSEcCtD
Nabumetone—Dysphagia—Capecitabine—colon cancer	0.000543	0.00347	CcSEcCtD
Nabumetone—Thrombophlebitis—Methotrexate—colon cancer	0.00054	0.00345	CcSEcCtD
Nabumetone—Anaemia—Vincristine—colon cancer	0.000537	0.00343	CcSEcCtD
Nabumetone—Agitation—Vincristine—colon cancer	0.000533	0.00341	CcSEcCtD
Nabumetone—Photosensitivity—Methotrexate—colon cancer	0.000533	0.0034	CcSEcCtD
Nabumetone—Angina pectoris—Capecitabine—colon cancer	0.000529	0.00338	CcSEcCtD
Nabumetone—Sweating increased—Capecitabine—colon cancer	0.000529	0.00338	CcSEcCtD
Nabumetone—Ill-defined disorder—Irinotecan—colon cancer	0.000525	0.00335	CcSEcCtD
Nabumetone—Anaemia—Irinotecan—colon cancer	0.000523	0.00334	CcSEcCtD
Nabumetone—Vertigo—Vincristine—colon cancer	0.000522	0.00333	CcSEcCtD
Nabumetone—Hepatic failure—Methotrexate—colon cancer	0.00052	0.00332	CcSEcCtD
Nabumetone—Leukopenia—Vincristine—colon cancer	0.00052	0.00332	CcSEcCtD
Nabumetone—Malaise—Irinotecan—colon cancer	0.00051	0.00325	CcSEcCtD
Nabumetone—Vertigo—Irinotecan—colon cancer	0.000508	0.00324	CcSEcCtD
Nabumetone—Dysuria—Capecitabine—colon cancer	0.000508	0.00324	CcSEcCtD
Nabumetone—Syncope—Irinotecan—colon cancer	0.000507	0.00324	CcSEcCtD
Nabumetone—Leukopenia—Irinotecan—colon cancer	0.000506	0.00323	CcSEcCtD
Nabumetone—Hypertension—Vincristine—colon cancer	0.000501	0.0032	CcSEcCtD
Nabumetone—Anaemia—Fluorouracil—colon cancer	0.0005	0.00319	CcSEcCtD
Nabumetone—Loss of consciousness—Irinotecan—colon cancer	0.000497	0.00317	CcSEcCtD
Nabumetone—Photosensitivity reaction—Capecitabine—colon cancer	0.000496	0.00316	CcSEcCtD
Nabumetone—Weight increased—Capecitabine—colon cancer	0.000494	0.00315	CcSEcCtD
Nabumetone—Cough—Irinotecan—colon cancer	0.000493	0.00315	CcSEcCtD
Nabumetone—Weight decreased—Capecitabine—colon cancer	0.000491	0.00314	CcSEcCtD
Nabumetone—Hyperglycaemia—Capecitabine—colon cancer	0.00049	0.00313	CcSEcCtD
Nabumetone—Hypertension—Irinotecan—colon cancer	0.000488	0.00312	CcSEcCtD
Nabumetone—Pneumonia—Capecitabine—colon cancer	0.000487	0.00311	CcSEcCtD
Nabumetone—Leukopenia—Fluorouracil—colon cancer	0.000485	0.00309	CcSEcCtD
Nabumetone—Anaphylactoid reaction—Methotrexate—colon cancer	0.000483	0.00308	CcSEcCtD
Nabumetone—Depression—Capecitabine—colon cancer	0.000483	0.00308	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.00048	0.00306	CcSEcCtD
Nabumetone—Acute coronary syndrome—Capecitabine—colon cancer	0.000477	0.00305	CcSEcCtD
Nabumetone—Renal failure—Capecitabine—colon cancer	0.000476	0.00304	CcSEcCtD
Nabumetone—Discomfort—Irinotecan—colon cancer	0.000476	0.00304	CcSEcCtD
Nabumetone—Myocardial infarction—Capecitabine—colon cancer	0.000475	0.00303	CcSEcCtD
Nabumetone—Oedema—Vincristine—colon cancer	0.000474	0.00302	CcSEcCtD
Nabumetone—Anaphylactic shock—Vincristine—colon cancer	0.000474	0.00302	CcSEcCtD
Nabumetone—Stomatitis—Capecitabine—colon cancer	0.000472	0.00301	CcSEcCtD
Nabumetone—Jaundice—Capecitabine—colon cancer	0.000472	0.00301	CcSEcCtD
Nabumetone—Confusional state—Irinotecan—colon cancer	0.000465	0.00297	CcSEcCtD
Nabumetone—Thrombocytopenia—Vincristine—colon cancer	0.000464	0.00296	CcSEcCtD
Nabumetone—Haematuria—Capecitabine—colon cancer	0.000462	0.00295	CcSEcCtD
Nabumetone—Oedema—Irinotecan—colon cancer	0.000461	0.00295	CcSEcCtD
Nabumetone—Anaphylactic shock—Irinotecan—colon cancer	0.000461	0.00295	CcSEcCtD
Nabumetone—Hyperhidrosis—Vincristine—colon cancer	0.000458	0.00292	CcSEcCtD
Nabumetone—Discomfort—Fluorouracil—colon cancer	0.000455	0.00291	CcSEcCtD
Nabumetone—Shock—Irinotecan—colon cancer	0.000454	0.0029	CcSEcCtD
Nabumetone—Agranulocytosis—Capecitabine—colon cancer	0.000452	0.00288	CcSEcCtD
Nabumetone—Thrombocytopenia—Irinotecan—colon cancer	0.000452	0.00288	CcSEcCtD
Nabumetone—Anorexia—Vincristine—colon cancer	0.000452	0.00288	CcSEcCtD
Nabumetone—Hyperhidrosis—Irinotecan—colon cancer	0.000446	0.00285	CcSEcCtD
Nabumetone—Confusional state—Fluorouracil—colon cancer	0.000446	0.00284	CcSEcCtD
Nabumetone—Anaphylactic shock—Fluorouracil—colon cancer	0.000442	0.00282	CcSEcCtD
Nabumetone—Oedema—Fluorouracil—colon cancer	0.000442	0.00282	CcSEcCtD
Nabumetone—Anorexia—Irinotecan—colon cancer	0.00044	0.00281	CcSEcCtD
Nabumetone—Haemoglobin—Capecitabine—colon cancer	0.000437	0.00279	CcSEcCtD
Nabumetone—Haemorrhage—Capecitabine—colon cancer	0.000435	0.00277	CcSEcCtD
Nabumetone—Thrombocytopenia—Fluorouracil—colon cancer	0.000433	0.00276	CcSEcCtD
Nabumetone—Liver function test abnormal—Methotrexate—colon cancer	0.000432	0.00276	CcSEcCtD
Nabumetone—Insomnia—Vincristine—colon cancer	0.000429	0.00274	CcSEcCtD
Nabumetone—Paraesthesia—Vincristine—colon cancer	0.000425	0.00272	CcSEcCtD
Nabumetone—Anorexia—Fluorouracil—colon cancer	0.000421	0.00269	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000421	0.00269	CcSEcCtD
Nabumetone—Visual impairment—Capecitabine—colon cancer	0.000419	0.00267	CcSEcCtD
Nabumetone—Insomnia—Irinotecan—colon cancer	0.000417	0.00266	CcSEcCtD
Nabumetone—Paraesthesia—Irinotecan—colon cancer	0.000414	0.00264	CcSEcCtD
Nabumetone—Decreased appetite—Vincristine—colon cancer	0.000412	0.00263	CcSEcCtD
Nabumetone—Dyspnoea—Irinotecan—colon cancer	0.000411	0.00263	CcSEcCtD
Nabumetone—Erythema multiforme—Capecitabine—colon cancer	0.000411	0.00262	CcSEcCtD
Nabumetone—Somnolence—Irinotecan—colon cancer	0.00041	0.00262	CcSEcCtD
Nabumetone—Fatigue—Vincristine—colon cancer	0.000408	0.00261	CcSEcCtD
Nabumetone—Dyspepsia—Irinotecan—colon cancer	0.000406	0.00259	CcSEcCtD
Nabumetone—Tinnitus—Capecitabine—colon cancer	0.000405	0.00259	CcSEcCtD
Nabumetone—Constipation—Vincristine—colon cancer	0.000405	0.00259	CcSEcCtD
Nabumetone—Asthma—Methotrexate—colon cancer	0.000404	0.00258	CcSEcCtD
Nabumetone—Decreased appetite—Irinotecan—colon cancer	0.000401	0.00256	CcSEcCtD
Nabumetone—Insomnia—Fluorouracil—colon cancer	0.0004	0.00255	CcSEcCtD
Nabumetone—Fatigue—Irinotecan—colon cancer	0.000398	0.00254	CcSEcCtD
Nabumetone—Paraesthesia—Fluorouracil—colon cancer	0.000397	0.00253	CcSEcCtD
Nabumetone—Pancreatitis—Methotrexate—colon cancer	0.000396	0.00253	CcSEcCtD
Nabumetone—Constipation—Irinotecan—colon cancer	0.000395	0.00252	CcSEcCtD
Nabumetone—Dyspnoea—Fluorouracil—colon cancer	0.000394	0.00251	CcSEcCtD
Nabumetone—Somnolence—Fluorouracil—colon cancer	0.000393	0.00251	CcSEcCtD
Nabumetone—Chills—Capecitabine—colon cancer	0.00039	0.00249	CcSEcCtD
Nabumetone—Dyspepsia—Fluorouracil—colon cancer	0.000389	0.00248	CcSEcCtD
Nabumetone—Arrhythmia—Capecitabine—colon cancer	0.000388	0.00248	CcSEcCtD
Nabumetone—Gastrointestinal pain—Vincristine—colon cancer	0.000387	0.00247	CcSEcCtD
Nabumetone—Decreased appetite—Fluorouracil—colon cancer	0.000384	0.00245	CcSEcCtD
Nabumetone—Alopecia—Capecitabine—colon cancer	0.000384	0.00245	CcSEcCtD
Nabumetone—Feeling abnormal—Irinotecan—colon cancer	0.00038	0.00243	CcSEcCtD
Nabumetone—Dysuria—Methotrexate—colon cancer	0.000378	0.00241	CcSEcCtD
Nabumetone—Gastrointestinal pain—Irinotecan—colon cancer	0.000377	0.00241	CcSEcCtD
Nabumetone—Body temperature increased—Vincristine—colon cancer	0.000375	0.00239	CcSEcCtD
Nabumetone—Abdominal pain—Vincristine—colon cancer	0.000375	0.00239	CcSEcCtD
Nabumetone—Flatulence—Capecitabine—colon cancer	0.000373	0.00238	CcSEcCtD
Nabumetone—Erectile dysfunction—Methotrexate—colon cancer	0.000372	0.00238	CcSEcCtD
Nabumetone—Photosensitivity reaction—Methotrexate—colon cancer	0.000369	0.00236	CcSEcCtD
Nabumetone—Abdominal pain—Irinotecan—colon cancer	0.000365	0.00233	CcSEcCtD
Nabumetone—Body temperature increased—Irinotecan—colon cancer	0.000365	0.00233	CcSEcCtD
Nabumetone—Feeling abnormal—Fluorouracil—colon cancer	0.000364	0.00232	CcSEcCtD
Nabumetone—Pneumonia—Methotrexate—colon cancer	0.000363	0.00231	CcSEcCtD
Nabumetone—Depression—Methotrexate—colon cancer	0.000359	0.00229	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000357	0.00228	CcSEcCtD
Nabumetone—Tremor—Capecitabine—colon cancer	0.000354	0.00226	CcSEcCtD
Nabumetone—Renal failure—Methotrexate—colon cancer	0.000354	0.00226	CcSEcCtD
Nabumetone—Stomatitis—Methotrexate—colon cancer	0.000351	0.00224	CcSEcCtD
Nabumetone—Ill-defined disorder—Capecitabine—colon cancer	0.000351	0.00224	CcSEcCtD
Nabumetone—Urticaria—Fluorouracil—colon cancer	0.000351	0.00224	CcSEcCtD
Nabumetone—Anaemia—Capecitabine—colon cancer	0.00035	0.00223	CcSEcCtD
Nabumetone—Body temperature increased—Fluorouracil—colon cancer	0.000349	0.00223	CcSEcCtD
Nabumetone—Hypersensitivity—Vincristine—colon cancer	0.000349	0.00223	CcSEcCtD
Nabumetone—Haematuria—Methotrexate—colon cancer	0.000344	0.00219	CcSEcCtD
Nabumetone—Malaise—Capecitabine—colon cancer	0.000341	0.00218	CcSEcCtD
Nabumetone—Vertigo—Capecitabine—colon cancer	0.00034	0.00217	CcSEcCtD
Nabumetone—Hypersensitivity—Irinotecan—colon cancer	0.00034	0.00217	CcSEcCtD
Nabumetone—Asthenia—Vincristine—colon cancer	0.00034	0.00217	CcSEcCtD
Nabumetone—Syncope—Capecitabine—colon cancer	0.000339	0.00217	CcSEcCtD
Nabumetone—Leukopenia—Capecitabine—colon cancer	0.000339	0.00216	CcSEcCtD
Nabumetone—Agranulocytosis—Methotrexate—colon cancer	0.000336	0.00215	CcSEcCtD
Nabumetone—Palpitations—Capecitabine—colon cancer	0.000334	0.00213	CcSEcCtD
Nabumetone—Loss of consciousness—Capecitabine—colon cancer	0.000333	0.00212	CcSEcCtD
Nabumetone—Asthenia—Irinotecan—colon cancer	0.000331	0.00211	CcSEcCtD
Nabumetone—Cough—Capecitabine—colon cancer	0.00033	0.00211	CcSEcCtD
Nabumetone—Hypertension—Capecitabine—colon cancer	0.000327	0.00209	CcSEcCtD
Nabumetone—Hypersensitivity—Fluorouracil—colon cancer	0.000326	0.00208	CcSEcCtD
Nabumetone—Haemoglobin—Methotrexate—colon cancer	0.000325	0.00208	CcSEcCtD
Nabumetone—Diarrhoea—Vincristine—colon cancer	0.000324	0.00207	CcSEcCtD
Nabumetone—Haemorrhage—Methotrexate—colon cancer	0.000324	0.00207	CcSEcCtD
Nabumetone—Anxiety—Capecitabine—colon cancer	0.000321	0.00205	CcSEcCtD
Nabumetone—Discomfort—Capecitabine—colon cancer	0.000318	0.00203	CcSEcCtD
Nabumetone—Diarrhoea—Irinotecan—colon cancer	0.000316	0.00202	CcSEcCtD
Nabumetone—Dry mouth—Capecitabine—colon cancer	0.000315	0.00201	CcSEcCtD
Nabumetone—Dizziness—Vincristine—colon cancer	0.000313	0.002	CcSEcCtD
Nabumetone—Pruritus—Fluorouracil—colon cancer	0.000313	0.002	CcSEcCtD
Nabumetone—Visual impairment—Methotrexate—colon cancer	0.000312	0.00199	CcSEcCtD
Nabumetone—Confusional state—Capecitabine—colon cancer	0.000311	0.00199	CcSEcCtD
Nabumetone—Oedema—Capecitabine—colon cancer	0.000309	0.00197	CcSEcCtD
Nabumetone—Erythema multiforme—Methotrexate—colon cancer	0.000306	0.00195	CcSEcCtD
Nabumetone—Dizziness—Irinotecan—colon cancer	0.000305	0.00195	CcSEcCtD
Nabumetone—Shock—Capecitabine—colon cancer	0.000304	0.00194	CcSEcCtD
Nabumetone—Diarrhoea—Fluorouracil—colon cancer	0.000302	0.00193	CcSEcCtD
Nabumetone—Thrombocytopenia—Capecitabine—colon cancer	0.000302	0.00193	CcSEcCtD
Nabumetone—Tinnitus—Methotrexate—colon cancer	0.000302	0.00193	CcSEcCtD
Nabumetone—Vomiting—Vincristine—colon cancer	0.000301	0.00192	CcSEcCtD
Nabumetone—Rash—Vincristine—colon cancer	0.000299	0.00191	CcSEcCtD
Nabumetone—Hyperhidrosis—Capecitabine—colon cancer	0.000299	0.00191	CcSEcCtD
Nabumetone—Dermatitis—Vincristine—colon cancer	0.000298	0.00191	CcSEcCtD
Nabumetone—Headache—Vincristine—colon cancer	0.000297	0.00189	CcSEcCtD
Nabumetone—Anorexia—Capecitabine—colon cancer	0.000294	0.00188	CcSEcCtD
Nabumetone—Vomiting—Irinotecan—colon cancer	0.000293	0.00187	CcSEcCtD
Nabumetone—Dizziness—Fluorouracil—colon cancer	0.000292	0.00187	CcSEcCtD
Nabumetone—Rash—Irinotecan—colon cancer	0.000291	0.00186	CcSEcCtD
Nabumetone—Dermatitis—Irinotecan—colon cancer	0.000291	0.00186	CcSEcCtD
Nabumetone—Chills—Methotrexate—colon cancer	0.00029	0.00185	CcSEcCtD
Nabumetone—Headache—Irinotecan—colon cancer	0.000289	0.00185	CcSEcCtD
Nabumetone—Alopecia—Methotrexate—colon cancer	0.000286	0.00183	CcSEcCtD
Nabumetone—Nausea—Vincristine—colon cancer	0.000281	0.0018	CcSEcCtD
Nabumetone—Vomiting—Fluorouracil—colon cancer	0.000281	0.00179	CcSEcCtD
Nabumetone—Insomnia—Capecitabine—colon cancer	0.000279	0.00178	CcSEcCtD
Nabumetone—Rash—Fluorouracil—colon cancer	0.000279	0.00178	CcSEcCtD
Nabumetone—Dermatitis—Fluorouracil—colon cancer	0.000278	0.00178	CcSEcCtD
Nabumetone—Paraesthesia—Capecitabine—colon cancer	0.000277	0.00177	CcSEcCtD
Nabumetone—Headache—Fluorouracil—colon cancer	0.000277	0.00177	CcSEcCtD
Nabumetone—Dyspnoea—Capecitabine—colon cancer	0.000275	0.00176	CcSEcCtD
Nabumetone—Nausea—Irinotecan—colon cancer	0.000274	0.00175	CcSEcCtD
Nabumetone—Dyspepsia—Capecitabine—colon cancer	0.000272	0.00174	CcSEcCtD
Nabumetone—Decreased appetite—Capecitabine—colon cancer	0.000268	0.00171	CcSEcCtD
Nabumetone—Fatigue—Capecitabine—colon cancer	0.000266	0.0017	CcSEcCtD
Nabumetone—Constipation—Capecitabine—colon cancer	0.000264	0.00169	CcSEcCtD
Nabumetone—Nausea—Fluorouracil—colon cancer	0.000262	0.00168	CcSEcCtD
Nabumetone—Ill-defined disorder—Methotrexate—colon cancer	0.000261	0.00167	CcSEcCtD
Nabumetone—Anaemia—Methotrexate—colon cancer	0.00026	0.00166	CcSEcCtD
Nabumetone—Feeling abnormal—Capecitabine—colon cancer	0.000254	0.00162	CcSEcCtD
Nabumetone—Malaise—Methotrexate—colon cancer	0.000254	0.00162	CcSEcCtD
Nabumetone—Vertigo—Methotrexate—colon cancer	0.000253	0.00162	CcSEcCtD
Nabumetone—Gastrointestinal pain—Capecitabine—colon cancer	0.000253	0.00161	CcSEcCtD
Nabumetone—Leukopenia—Methotrexate—colon cancer	0.000252	0.00161	CcSEcCtD
Nabumetone—Cough—Methotrexate—colon cancer	0.000246	0.00157	CcSEcCtD
Nabumetone—Urticaria—Capecitabine—colon cancer	0.000245	0.00157	CcSEcCtD
Nabumetone—Body temperature increased—Capecitabine—colon cancer	0.000244	0.00156	CcSEcCtD
Nabumetone—Abdominal pain—Capecitabine—colon cancer	0.000244	0.00156	CcSEcCtD
Nabumetone—Discomfort—Methotrexate—colon cancer	0.000237	0.00151	CcSEcCtD
Nabumetone—Confusional state—Methotrexate—colon cancer	0.000232	0.00148	CcSEcCtD
Nabumetone—Anaphylactic shock—Methotrexate—colon cancer	0.00023	0.00147	CcSEcCtD
Nabumetone—Hypersensitivity—Capecitabine—colon cancer	0.000228	0.00145	CcSEcCtD
Nabumetone—Thrombocytopenia—Methotrexate—colon cancer	0.000225	0.00144	CcSEcCtD
Nabumetone—Hyperhidrosis—Methotrexate—colon cancer	0.000222	0.00142	CcSEcCtD
Nabumetone—Asthenia—Capecitabine—colon cancer	0.000222	0.00141	CcSEcCtD
Nabumetone—Anorexia—Methotrexate—colon cancer	0.000219	0.0014	CcSEcCtD
Nabumetone—Pruritus—Capecitabine—colon cancer	0.000218	0.00139	CcSEcCtD
Nabumetone—Diarrhoea—Capecitabine—colon cancer	0.000211	0.00135	CcSEcCtD
Nabumetone—Insomnia—Methotrexate—colon cancer	0.000208	0.00133	CcSEcCtD
Nabumetone—Paraesthesia—Methotrexate—colon cancer	0.000206	0.00132	CcSEcCtD
Nabumetone—Dyspnoea—Methotrexate—colon cancer	0.000205	0.00131	CcSEcCtD
Nabumetone—Somnolence—Methotrexate—colon cancer	0.000204	0.0013	CcSEcCtD
Nabumetone—Dizziness—Capecitabine—colon cancer	0.000204	0.0013	CcSEcCtD
Nabumetone—Dyspepsia—Methotrexate—colon cancer	0.000202	0.00129	CcSEcCtD
Nabumetone—Decreased appetite—Methotrexate—colon cancer	0.0002	0.00128	CcSEcCtD
Nabumetone—Fatigue—Methotrexate—colon cancer	0.000198	0.00127	CcSEcCtD
Nabumetone—Vomiting—Capecitabine—colon cancer	0.000196	0.00125	CcSEcCtD
Nabumetone—Rash—Capecitabine—colon cancer	0.000195	0.00124	CcSEcCtD
Nabumetone—Dermatitis—Capecitabine—colon cancer	0.000195	0.00124	CcSEcCtD
Nabumetone—Headache—Capecitabine—colon cancer	0.000193	0.00123	CcSEcCtD
Nabumetone—Feeling abnormal—Methotrexate—colon cancer	0.000189	0.00121	CcSEcCtD
Nabumetone—Gastrointestinal pain—Methotrexate—colon cancer	0.000188	0.0012	CcSEcCtD
Nabumetone—Nausea—Capecitabine—colon cancer	0.000183	0.00117	CcSEcCtD
Nabumetone—Urticaria—Methotrexate—colon cancer	0.000183	0.00117	CcSEcCtD
Nabumetone—Body temperature increased—Methotrexate—colon cancer	0.000182	0.00116	CcSEcCtD
Nabumetone—Abdominal pain—Methotrexate—colon cancer	0.000182	0.00116	CcSEcCtD
Nabumetone—Hypersensitivity—Methotrexate—colon cancer	0.000169	0.00108	CcSEcCtD
Nabumetone—Asthenia—Methotrexate—colon cancer	0.000165	0.00105	CcSEcCtD
Nabumetone—Pruritus—Methotrexate—colon cancer	0.000163	0.00104	CcSEcCtD
Nabumetone—Diarrhoea—Methotrexate—colon cancer	0.000157	0.001	CcSEcCtD
Nabumetone—Dizziness—Methotrexate—colon cancer	0.000152	0.00097	CcSEcCtD
Nabumetone—Vomiting—Methotrexate—colon cancer	0.000146	0.000933	CcSEcCtD
Nabumetone—Rash—Methotrexate—colon cancer	0.000145	0.000925	CcSEcCtD
Nabumetone—Dermatitis—Methotrexate—colon cancer	0.000145	0.000924	CcSEcCtD
Nabumetone—Headache—Methotrexate—colon cancer	0.000144	0.000919	CcSEcCtD
Nabumetone—Nausea—Methotrexate—colon cancer	0.000137	0.000872	CcSEcCtD
